Reversine: Benchmark Aurora Kinase Inhibitor for Cancer Cell Cycle Research

Executive Summary: Reversine (6-N-cyclohexyl-2-N-(4-morpholin-4-ylphenyl)-7H-purine-2,6-diamine) is a small molecule inhibitor with nanomolar IC50 against Aurora kinases A (150 nM), B (500 nM), and C (400 nM), disrupting mitotic checkpoints and cell proliferation (APExBIO). It is insoluble in water but dissolves efficiently in DMSO (≥19.65 mg/mL) and ethanol (≥6.69 mg/mL with warming/sonication). Reversine induces dedifferentiation in murine myoblasts, inhibits proliferation in multiple cervical cancer lines (HeLa, U14, Siha, Caski, C33A), and synergistically reduces tumor weight in murine models, especially when co-administered with aspirin. Its mechanism enables in-depth analysis of Aurora kinase signaling and mitotic regulation, positioning it as a gold standard in translational cancer research (Kaisaria et al., 2019).

Biological Rationale

Aurora kinases (A, B, and C) are serine/threonine kinases essential for eukaryotic mitosis. They govern centrosome maturation, spindle assembly, and chromosome segregation. Disruption of Aurora kinase signaling leads to mitotic errors, aneuploidy, and tumorigenesis (Kaisaria et al., 2019). Aberrant Aurora kinase activity is observed in a range of human cancers, including cervical and lung carcinoma. The mitotic checkpoint (spindle assembly checkpoint) ensures accurate chromosome segregation by regulating anaphase onset via the mitotic checkpoint complex (MCC). Small molecule inhibitors like Reversine enable precise perturbation of this checkpoint, providing mechanistic insight and potential therapeutic leverage (see comparative review).

Mechanism of Action of Reversine

Reversine is a cell-permeable compound that competitively inhibits the ATP-binding pockets of Aurora kinases A, B, and C. Its structure enables high-affinity binding, with nanomolar IC50 values (A: 150 nM, B: 500 nM, C: 400 nM; measured at 25°C, kinase buffer pH 7.5) (APExBIO). Inhibition of Aurora kinases disrupts phosphorylation cascades critical for spindle checkpoint signaling, leading to failure of proper chromosome alignment and segregation. This blockade arrests cells in mitosis or triggers apoptosis, particularly in rapidly dividing tumor cells. Reversine also induces dedifferentiation in myoblasts and modulates key components of the MCC, including Mad2 and p31^comet, intersecting with broader mitotic checkpoint control (Kaisaria et al., 2019).

Evidence & Benchmarks

• Reversine inhibits Aurora kinase A (IC50: 150 nM), B (500 nM), and C (400 nM) in biochemical kinase assays at 25°C, pH 7.5 (APExBIO).
• Disruption of Aurora kinase activity by Reversine causes mitotic arrest and apoptosis in HeLa, U14, Siha, Caski, and C33A cervical cancer cell lines (24–72 h, 1–10 μM) (Kaisaria et al., 2019).
• In murine cervical cancer models, Reversine (administered at 5 mg/kg, intraperitoneally, daily for 14 days) reduced tumor weight and volume by >50% compared to untreated controls. Co-administration with aspirin enhanced these effects synergistically (APExBIO).
• Reversine is insoluble in water but dissolves in DMSO (≥19.65 mg/mL) and ethanol (≥6.69 mg/mL with gentle warming and sonication), facilitating in vitro and in vivo dosing (APExBIO).
• Reversine-induced mitotic checkpoint disruption is corroborated by altered phosphorylation of key checkpoint proteins and suppression of MCC activity, as established in mechanistic kinase assays (Kaisaria et al., 2019).

Applications, Limits & Misconceptions

Reversine is widely used to investigate the role of Aurora kinases in cancer cell cycle regulation, apoptosis induction, and cell fate reprogramming. Its specificity and cell permeability make it ideal for dissecting mitotic checkpoint signaling and exploring combination therapies in preclinical studies. The product is intended strictly for research use and is not suitable for diagnostic or therapeutic purposes.

Common Pitfalls or Misconceptions

• Reversine is not soluble in water; improper dissolution reduces efficacy. Use DMSO or ethanol as recommended (APExBIO).
• Stock solutions are unstable at room temperature and should not be stored long-term; prepare fresh aliquots prior to use.
• Reversine is not selective for non-Aurora kinases; off-target effects at high concentrations (>10 μM) have not been fully excluded.
• It is not approved for medical or diagnostic applications; use is limited to controlled laboratory research.
• Reversine-induced dedifferentiation is context-dependent and may not occur in all cell types or under all conditions.

Workflow Integration & Parameters

Reversine (A3760) is supplied as a solid by APExBIO and should be stored at -20°C. For in vitro applications, dissolve in DMSO to a stock concentration of 10–20 mM; dilute to final working concentrations (typically 0.1–10 μM) in culture media immediately before use. For in vivo studies, dissolve in DMSO or ethanol, then further dilute in an appropriate vehicle for injection. Use solutions promptly to avoid degradation. Integration with cell cycle analysis, immunoblotting for phospho-Aurora kinase substrates, and apoptosis assays is recommended (see advanced protocols guide for troubleshooting and optimization). This article extends previous protocol guides by detailing mechanistic benchmarks and providing updated stability data.

Conclusion & Outlook

Reversine is a validated, potent inhibitor of Aurora kinases with broad utility in mitotic regulation and cancer cell research. Its robust solubility and reproducible efficacy have established it as a cornerstone for dissecting spindle assembly checkpoint signaling and apoptosis induction in both in vitro and in vivo systems. Ongoing studies continue to clarify its full spectrum of cellular effects and expand its application in combination therapy research. For further comparative mechanistic insights, see the Precision Aurora Kinase Inhibitor review, which this article updates with new in vivo synergy results and solubility parameters.

For product details and ordering, visit the Reversine product page at APExBIO.